Sharon Mates is CEO & Chairman +1 at Intra-Cellular Therapies, Inc. (ITCI). They have made 23 open-market trades across 1 company since 2014, most recently 2025-04-02.
CIK 0001585699
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 23 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITCI | 190,000 | $25.1M |
Shares reported on the most recent Form 4, priced at the 2025-03-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL · 10b5-1 | 2024-12-04 | 2024-12-06 | $84.79 | $15.4M | +3.1% | -2.8% | +56.0% |
| ITCI | SELL · 10b5-1 | 2024-08-29 | 2024-08-30 | $72.68 | $9.8M | +2.6% | -0.2% | +16.8% |
| ITCI | SELL · 10b5-1 | 2024-08-26 | 2024-08-28 | $73.53 | $14.1M | +1.1% | +0.7% | +18.8% |
| ITCI | SELL · 10b5-1 | 2024-08-21 | 2024-08-23 | $75.03 | $18.0M | -2.7% | +1.8% | +14.8% |
| ITCI | SELL · 10b5-1 | 2024-03-07 | 2024-03-11 | $66.06 | $8.1M | +5.2% | +3.5% | +6.2% |
| ITCI | SELL · 10b5-1 | 2024-02-26 | 2024-02-27 | $69.80 | $3.1M | -7.1% | -4.7% | -9.7% |
| ITCI | SELL · 10b5-1 | 2024-02-02 | 2024-02-05 | $66.95 | $3.4M | +8.5% | -4.3% | +2.9% |
| ITCI | SELL · 10b5-1 | 2024-01-16 | 2024-01-18 | $66.29 | $23.3M | +4.6% | +12.7% | +17.3% |
| ITCI | SELL · 10b5-1 | 2023-09-18 | 2023-09-19 | $53.94 | $10.8M | -4.2% | -8.5% | +20.1% |
| ITCI | SELL | 2023-03-10 | 2023-03-13 | $43.76 | $5.5M | +0.7% | +28.8% | +41.3% |
| ITCI | SELL | 2023-02-24 | 2023-02-27 | $47.03 | $2.1M | -8.8% | +17.5% | +22.5% |
| ITCI | SELL | 2023-02-21 | 2023-02-22 | $46.79 | $2.5M | +3.4% | +1.6% | +34.4% |
| ITCI | SELL | 2022-12-13 | 2022-12-15 | $55.00 | $1.8M | +0.0% | -4.4% | -14.1% |
| ITCI | SELL | 2022-02-24 | 2022-02-25 | $51.98 | $2.3M | +3.9% | +11.7% | +6.7% |
| ITCI | SELL | 2022-02-22 | 2022-02-23 | $55.39 | $3.1M | +3.5% | +18.2% | +10.8% |
| ITCI | SELL | 2022-01-10 | 2022-01-11 | $40.78 | $3.4M | +9.8% | +28.0% | +55.4% |
| ITCI | SELL | 2021-10-14 | 2021-10-18 | $40.00 | $2.0M | +5.6% | -4.0% | -3.8% |
| ITCI | SELL | 2021-02-19 | 2021-02-22 | $39.23 | $2.2M | -13.6% | -20.0% | -0.6% |
| ITCI | SELL | 2021-01-11 | 2021-01-12 | $32.01 | $2.7M | +1.1% | +16.4% | -5.5% |
| ITCI | SELL | 2021-01-04 | 2021-01-05 | $31.30 | $2.6M | +6.6% | +9.8% | +2.5% |
| ITCI | SELL | 2020-11-10 | 2020-11-12 | $26.34 | $2.6M | -0.9% | -1.9% | +46.4% |
| ITCI | SELL | 2020-11-04 | 2020-11-06 | $25.00 | $1.3M | +4.7% | +2.6% | +40.1% |
| ITCI | SELL | 2020-01-09 | 2020-01-10 | $26.16 | $2.2M | -4.4% | -17.9% | -36.7% |
| ITCI | SELL | 2020-01-06 | 2020-01-08 | $30.28 | $2.8M | -5.1% | -20.3% | -43.0% |
| ITCI | SELL | 2020-01-02 | 2020-01-03 | $32.44 | $915K | -12.7% | -25.2% | -52.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.